NCT03436563View on ClinicalTrials.gov

M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

August 8, 2023

Study Completion Date

August 8, 2023

Conditions
Colon AdenocarcinomaHigh-Frequency Microsatellite InstabilityMetastatic Malignant Solid NeoplasmRectal AdenocarcinomaRefractory Colorectal CarcinomaStage IV Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8
Interventions
BIOLOGICAL

Anti-PD-L1/TGFbetaRII Fusion Protein M7824

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03436563 - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Biotech Hunter | Biotech Hunter